TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07629726: A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms

Sponsor: Kyowa Kirin Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 72 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07629726 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07629726 Rescue Dossier →